

Head and Neck Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:

Mehir Tharani

Clinical Research Coordinators:

Bao-An Huynh

Natalie Arechiga

Erin Palmer-Torrison

Anastasiia Reipolska



■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Neoadjuvant HNSCC

ETCTN 10706

Cemiplimab vs CDX-1140 + Sx
Locally Advanced Resectable HNSCC
PI: Dr. Villaflor
Coord: A. Reipolska
Accrual: 0/5

UCI 25-230

Sx +/- APG-157 (PO),
Induciton CRT +/- APG-157 + Sx
Locally Advanced HNSCC
PI: Dr. Haidar
Coord: TBD
Accrual: 0/10

ETCTN 10721

Carbo/Taxol +/- Cemiplimab, Sx
Locally Advanced SNSCC
PI: Dr. Kuan
Coord: TBD
Accrual: 0/5

Definitive HNSCC

UCI 22-132

De-escalated Radiation HPV 16+ SCC OPC
PI: Dr. Chen
Coord: E. Palmer-Torrison
Accrual: 26/111

UCI 21-173

AHCC w/ SOC Tx
HPV+ HNSCC
PI: Dr. Nabar
Coord: A. Reipolska
Mushroom Extract
Accrual: 6/34

HN009

Cisplatin Q3 weeks vs Weekly
Locally Advanced HNSCC
PI: Dr. Attarian
Coord: A. Reipolska
Accrual: 1/5
Temporarily Suspended for data analysis

Re-radiation

EA3191

Pembrolizumab
Adjuvant Recurrent/2ndary HNSCC
Attarian
Coord: N. Arechiga
Accrual: 0/5

Adjuvant

EA3132 (TP53)

XRT +/- Cisplatin
Adjuvant
Dr. Attarian
Coord: A. Reipolska
Accrual: 0/5



1st Line Recurrent/Metastatic HNSCC

UCI 24-130

HPV injection + Pembro
1st line Recurrent/Metastatic HPV+
PI: Attarian
Coord: Anastasiia R.
Accrual: 0/5

Temporarily Suspended

RTOG 3521

Gem+Cis+ Tori
1st line Recurrent/Metastatic NPC
PI: Attarian
Coord: N. Arechiga
Accrual: 1/5

Recurrent/Metastatic

UCI 25-49

Petosemtamab vs Phys Choice
Recurrent HNSCC
PI: Attarian
CRC: E. Palmer-Torrison
Accrual: 0/5
*closed to opc

S2101

Nivo + Cabozantinib
HNSCC, Melanoma
PI: Dr. Vaidya
Coord: Natalie A
Accrual: 4/5

Alliance A092105

2nd line Ipi/Nivo +/- Cabozantinib
Recurrent NPC
PI: Attarian
Coord: B. Huynh
Accrual: 1/5

EA3231

BRAF Agent vs Cabozantinib
Recurrent Thyroid Cancer
PI: Attarian
Coord: E. Palmer-Torrison
Accrual: 0/5



Broad Phase 1 Trials

UCI 25-106

BMS ADC TOPO1 inhibitor
HNSCC, 2L+ sq/nsq NSCLC, TNBC
PI: Dr. Nabar
Coord: N. Arechiga
Accrual: 0/5

UCI 25-170

Immunogenesis
HNSCC, 2L+ sq/nsq NSCLC, TNBC
Dr. Villafior
Coord: TBD
Accrual: 0/5

UCI 22-09

B7-H4–targeted antibody-drug
conjugate
PI: Dr. Parajuli
CRC: N. Arechiga
Accrual: 6/10
Waitlist only

UCI 24-113

Ikaros zinc finger
HNSCC, Melanoma, NSCLC, TNBC
PI: Dr. Chow
Coord: Natalie A.
Accrual: 5/10

UCI 24-142 (KaliVir)

Squamous cell basket, including SCCN and
SCCL, Dermatologic malignancies (e.g., Merkel
cell carcinoma, cutaneous squamous cell
carcinoma), RCC, Urothelial carcinoma (other
GU malignancies such as PCA following a
discussion with us) Cervical cancer, MSS-CRC
VET3-TGI (sq/intratumoral) +/-
Pembrolizumab
PI: Uchio
Coord: TBD
Accrual: 1/4
Waitlist only

Brain Fog

UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*

BREAST COHORT FULL

PI: Chan

CRC: Randy Kang

Accrual: 26/39

Oral Pain

UCI 26-01

Oral mouthwash

PI: Attarian

CRC: TBD

Accrual: TBD

UCI 25-48

Riluzole PO vs. Placebo PO
Preventative worsening of cognitive
function

PI: Chan

CRC: Madeleine Phan

Accrual: 4/20